Jamaica adds RotaTeq to child vacc program
The Pharmaceutical and Regulatory Affairs Branch of the Jamaican Ministry of Health's Standards and Regulation Division, is expected to add US drug major Merck & Co's Rotateq vaccine against the rotavirus, to the country's child immunization program, according to a report in the Jamaica Observer.
A three-year trial of the vaccine was conducted in Jamaica, along with 10 other countries including the USA, with the results reviewed by the Jamaican drug regulator's Product Registration Committee. The study was recently commented on by the US Centers for Disease Control and Prevention (CDC), which found that intussusception reports were within the expected range (Marketletter March 26).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze